Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Brandes Investment Partners LP

Brandes Investment Partners LP increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 66.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,731,180 shares of the company’s stock after acquiring an additional 2,296,691 shares during the quarter. Brandes Investment Partners LP owned approximately 1.16% of Elanco Animal Health worth $69,405,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ELAN. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health in the third quarter worth $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the third quarter worth $35,000. Venturi Wealth Management LLC boosted its position in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after buying an additional 1,601 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares during the period. Finally, SRS Capital Advisors Inc. boosted its position in shares of Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after buying an additional 3,411 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.5 %

Elanco Animal Health stock opened at $10.47 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business’s 50-day simple moving average is $11.49 and its 200-day simple moving average is $12.80. The firm has a market capitalization of $5.18 billion, a PE ratio of 26.16, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52 week low of $10.03 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Stifel Nicolaus reduced their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Morgan Stanley reduced their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Finally, UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.17.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares of the company’s stock, valued at approximately $1,105,903.10. The trade was a 10.93 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.57% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.